医学
导管癌
乳腺癌
随机对照试验
肿瘤科
临床试验
内科学
混淆
中期分析
前瞻性队列研究
临时的
阶段(地层学)
外科
放射科
入射(几何)
癌症
原位癌
随机化
原位
乳房磁振造影
佐剂
保乳手术
内分泌系统
不利影响
作者
Simone Schiaffino,Andrea Cozzi
摘要
Ductal carcinoma in situ (DCIS) is almost invariably treated with surgery and adjuvant therapies (radiation and, frequently, endocrine therapy).The apparent mismatch between the intensity of treatment and the nature of DCIS-a nonobligate precursor of invasive cancer-has led to the exploration of potential strategies for therapeutic de-escalation.In this regard, preliminary results that have lately emerged from three major prospective trials seem promising but inconclusive.The COMET randomized clinical trial found active monitoring non-inferior to surgery at 2 years (4.2% vs. 5.9% ipsilateral invasive cancer), but more than 70% of the monitoring arm took endocrine therapy, potentially affecting the event rate [1].LORD, the largest prospective trial, saw roughly three-quarters of informed women choose surveillance over immediate surgery and showed similar incidences of invasive cancer across the treatment strategies at a pre-specified interim analysis, but only after the trial traded randomization for patient preference, potentially introducing confounding by indication [2].LORETTA, a single-arm endocrine-only trial, was stopped early when 5-year ipsilateral invasive incidence reached 9.8%, over its pre-specified 7% safety ceiling [3].
科研通智能强力驱动
Strongly Powered by AbleSci AI